Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06529302 · ClinicalTrials.gov registry record
The OPBC-07/microNAC Study
A clinical trial of Breast Cancer, sponsored by University Hospital, Basel, Switzerland.
- Active
- Registry status
- 2,000
- Enrollment target
- 20
- Study locations
NCT06529302: Active study of Breast Cancer, sponsored by University Hospital, Basel, Switzerland.
NCT06529302 is a study of Breast Cancer that is active but no longer recruiting, run by University Hospital, Basel, Switzerland. The registered enrollment target is 2,000 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06529302, a study of Breast Cancer, is active but no longer recruiting, sponsored by University Hospital, Basel, Switzerland.
- ACTIVE NOT RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this multicenter retrospective cohort study is to determine the safety of omission of axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy.
Primary Outcome
Assessment of the incidence of any axillary recurrence, which is defined as isolated or combined with local or distant recurrence.
Conditions Studied
Study Locations (20)
New York
- NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
- Montefiore Medical Center - New York
- University of Rochester - Rochester
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California - San Francisco
- Providence Saint John's Cancer Institute - Santa Monica
Pennsylvania
- University of Pennsylvania - Philadelphia
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Washington
- Swedish Cancer Institute - Seattle
- University of Washington - Seattle
Arizona
- Valleywise Health Medical Center - Phoenix
Florida
- University of Miami - Coral Gables
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2025-06 |
What the registry record for NCT06529302 still lists
NCT06529302 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (29% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06529302 names 20 study sites across 12 states, led by New York, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06529302 about?
NCT06529302 is a clinical study titled "The OPBC-07/microNAC Study". The aim of this multicenter retrospective cohort study is to determine the safety of omission of axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy.
What is the current status of trial NCT06529302?
This trial is currently active not recruiting. The enrollment target is 2,000 participants. The study started on 2024-05-15. Estimated completion is 2025-06.
What conditions does trial NCT06529302 study?
This clinical trial studies the following conditions: Breast Cancer.
Who is sponsoring clinical trial NCT06529302?
This trial is sponsored by University Hospital, Basel, Switzerland, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06529302 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06529302's enrollment target sits among peer trials
2,000 69th of 1224 higher than 1,156 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI